Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CYP51A1 is a monooxygenase enzyme belonging to the cytochrome P450 superfamily. It catalyzes the 14α-demethylation of lanosterol, a crucial step in the biosynthesis of cholesterol in animals, ergosterol in fungi, and other sterols in plants. This enzyme is highly conserved across eukaryotes and is a major target for antifungal drugs (azole antifungals) that disrupt ergosterol production in fungi. In humans, mutations or dysregulation can impact cholesterol synthesis, and it has been explored as a target for herbicides and cholesterol-lowering agents.
Inhibition of fungal CYP51 by binding to its heme group active site as a noncompetitive inhibitor, disrupting ergosterol production.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytochrome P450 family 51 subfamily A member 1 (CYP51A1).